Autologous Transplantation in Patients with Acute Myeloid Leukemia in First Remission with IL-2-Cultured Marrow or Peripheral Blood Stem Cells Followed by in vivo IL-2

1995 ◽  
Vol 18 (1) ◽  
pp. 44-47 ◽  
Author(s):  
H.-G. Klingemann ◽  
C.J. Eaves ◽  
M.J. Barnett ◽  
A.C. Eaves ◽  
D.E. Hogge ◽  
...  
Keyword(s):  
Stem Cells ◽  
Acute Myeloid Leukemia ◽  
Peripheral Blood ◽  
Myeloid Leukemia ◽  
Autologous Transplantation ◽  
Peripheral Blood Stem Cells ◽  
Blood Stem Cells ◽  
First Remission ◽  
Acute Myeloid

Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia

2007 ◽  
Vol 25 (2) ◽  
pp. 84-89 ◽  
Author(s):  
Felicetto Ferrara ◽  
Assunta Viola ◽  
Carolina Copia ◽  
Claudio Falco ◽  
Rossella D'Elia ◽  
...  
Keyword(s):  
Stem Cells ◽  
Acute Myeloid Leukemia ◽  
Peripheral Blood ◽  
Myeloid Leukemia ◽  
Peripheral Blood Stem Cells ◽  
Blood Stem Cells ◽  
Acute Myeloid

Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients

Blood ◽  
2011 ◽  
Vol 117 (3) ◽  
pp. 936-941 ◽  
Author(s):  
Mei Guo ◽  
Kai-Xun Hu ◽  
Chang-Lin Yu ◽  
Qi-Yun Sun ◽  
Jian-Hui Qiao ◽  
...  
Keyword(s):  
Stem Cells ◽  
Acute Myeloid Leukemia ◽  
Complete Remission ◽  
Elderly Patients ◽  
Peripheral Blood ◽  
Myeloid Leukemia ◽  
Control Group ◽  
Peripheral Blood Stem Cells ◽  
Blood Stem Cells ◽  
Acute Myeloid

Abstract Treatment outcome of acute myeloid leukemia (AML) in elderly patients remains unsatisfactory. It has been shown that the infusion of granulocyte colony-stimulating factor–mobilized donor peripheral blood stem cells (G-PBSCs) can enhance graft-versus-leukemia effects and speed hematopoietic recovery. Fifty-eight AML patients aged 60-88 years were randomly assigned to receive induction chemotherapy with cytarabine and mitoxantrone (control group; n = 28) or it plus human leukocyte antigen–mismatched G-PBSCs (G-PBSC group; n = 30). Patients who achieved complete remission received another 2 cycles of postremission therapy with intermediate-dose cytarabine or it plus G-PBSCs. The complete remission rate was significantly higher in the G-PBSC group than in the control group (80.0% vs 42.8%; P = .006). The median recovery times of neutrophils and platelets were 11 days and 14.5 days, respectively, in the G-PBSC group and 16 days and 20 days, respectively, in the control group after chemotherapy. The 2-year probability of disease-free survival was significantly higher in the G-PBSC group than in the control group (38.9% vs 10.0%; P = .01). No graft-versus-host disease was observed in any patient. Persistent donor microchimerism was successfully detected in all of the 4 female patients. These results indicate that G-PBSCs in combination with conventional chemotherapy may provide a promising treatment method for AML in elderly patients.

Sign in / Sign up

Export Citation Format

Share Document